The role of hemostatic disorders in the progression of chronic kidney disease

DOI: https://doi.org/10.31450/ukrjnd.4(64).2019.07
Keywords: сhronic kidney disease, glomerulonephritis, diabetic nephropathy, hemostasis, intravascular coagulation syndrome, thrombosis.

Abstract

Chronic kidney disease (CKD) has become a global public health problem because of its high prevalence and the accompanying increase in the risk of end-stage renal disease, cardiovascular disease, and premature death. At present there is a number of experimental and clinical data that show that one of the important mechanisms of the pathogenesis of CKD is a violation of the blood coagulation system (hemostasis) both locally in the kidneys and with the capture of the microcirculatory channel of other organs, therefore an important task for specialists in the  nephrology, as well as doctors of other specialties is  understanding  the functioning of the system of hemostasis in normal and in various kidney diseases and the correction of this pathology with drugs.

There are several types of haemostasis disorders that may occur in CKD: disseminated intravascular coagulation syndrome (DIC), arterial and venous thrombosis and bleeding.

In this review, we tried to determine the place of the DIC in the development and progress of the CKD and to assess the prospects for further research.

Downloads

Download data is not yet available.

References

1. Kolesnyk  M.  Innovative  directions  of  CKD  prevention  and  treatment.  Ukr  J  Nephr Dial. 2019;1(61):3-12. doi: 10.31450/ukrjnd.1(61).2019.01.

2. Suarez-Alvarez B, Liapis H, Anders H. Links between coagulation, inflammation, regeneration, and fibrosis in kidney pathology. Laboratory Investigation. 2016; 96:378–390. doi: 10.1038/labinvest.2015.164.

3. Jalal D, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin. Thromb. Hemost. 2010; 36(1): 34-40. doi: 10.1055/s-0030-1248722.

4. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev. 2011; 25: 271-278. doi: 10.1016/j.blre.2011.07.001.

5. Taylor F, Toh C, Hoots W, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH): Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.

6. Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625-631. doi: 10.1097/01.CCM.0000202209.42491.38.

7. Levi M, van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost. 2014;40:874-880. doi: 10.1055/s-0034-1395155.

8. Singh N, Pati H, Tyagi S. Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to D-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis.2017;23(5):460-465. doi.10.1177/1076029615615959.

9. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thrombos Haemost. 2013;11:761-767. doi: 10.1111/jth.12155.

10. Bakhtiari K, Meijers J, de Jonge E, et al. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004;32:2416-2421.

11. Wada H, Hatada T, Okamoto K, et al. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol. 2010;85(9):691-694. doi: 10.1002/ajh.21783.

12. Papageorgiou Ch,  Jourdi G, Adjambri E, Walborn A, et al. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clinical and Applied Thrombosis/Hemostasis. 2018;24:8-28. doi: 10.1177/1076029618806424.

13. Wada H, Asakura H, Okamoto K, et al. Japanese Society of Thrombosis Hemostasis/DIC Subcommittee: expert consensus for the treatment of DIC in Japan. Thromb Res. 2010;125(1):6-11.  doi: 10.1186/2052-0492-2-15.

14.  Umemura Y, Yamakawa K, Kiguchi T, et al. Design and evaluation of new unified criteria for disseminated intravascular coagulation based on the Japanese Association for Acute Medicine Criteria. Clin Appl Thromb Hemost. 2016; 22(2): 153-160. doi: 10.1177/1076029615591169.

15. Boral B, Williams D, Boral L. Disseminated Intravascular Coagulation.  Am J Clin Pathol. 2016;146:670-680. doi:10.1093/AJCP/AQW195.

16. Singh B, Hanson A, Alhurani R. Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients (2004-2010): a population-based study. Chest. 2013;143:1235-1242. doi: 10.1378/chest.12-2112.

17. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(Suppl):26–34. doi:10.1097/CCM.0b013e3181c98d21.

18. Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29:29–40. doi: 10.1093/ndt/gft209.

19. Wu Y. Contact pathway of coagulation and inflammation. Thromb J. 2015;13:17. doi: 10.1186/s12959-015-0048-y

20. Molino D, de Lucia D, Gaspare de Santo N. Coagulation disorders in uremia. Semin. Nephrol. 2006;26:46-51. doi: 10.1016/j.semnephrol.2005.06.011.

21. Salem H, Whitworth J, Koutts J. Hypercoagulation in glomerulonephritis. British Medical Journal. 1981;282:2083-2085.

22. Margetic S. Inflammation and haemostasis. Biochemia Medica. 2012:49–62. doi: 10.11613/BM.2012.006.

23. Singhal R, Brimble K. Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thromb Res. 2006; 118: 397–407. doi: 10.1016/j.thromres.2005.03.030.

24. Kerlin B, Ayoob R, Smoyer W. Epidemiology and Pathophysiology of Nephrotic Syndrome–Associated Thromboembolic Disease. Clin J Am Soc Nephrol. 2012; 7: 513–520. doi: 10.2215/CJN.10131011.

25. Sextona M, Clarksona M, Mazura W, Planta J. Serum D-Dimer Concentrations in Nephrotic Syndrome Track with Albuminuria, Not Estimated Glomerular Filtration Rate. Am J Nephrol. 2012;36:554–560. doi: 10.1159/000345475.

26. Rabelink T, Zwaginga J, Koomans H. Thrombosis and hemostasis in renal disease. Kidney Int. 1994; 46:287–296.

27. Radhakrishnan J. Venous thromboembolism and membranous nephropathy: so what’s new? Clin J Am Soc Nephrol. 2012;7:3–4. doi: 10.2215/CJN.11791111.

28. Domingueti C, Foscolo R, Reis J,  Campos F, et al. Association of Haemostatic and Inflammatory Biomarkers with Nephropathy in Type 1 Diabetes Mellitus. Journal of Diabetes Research. 2016; Article ID 2315260:8. doi:10.1155/2016/2315260.

29. Goldberg R. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. The Journal of Clinical Endocrinology & Metabolism. 2009;94:3171–3182. doi: 10.1210/jc.2008-2534.

30. Cheng H, Harris R. Renal Endothelial Dysfunction in Diabetic Nephropathy. Cardiovasc Hematol Disord Drug Targets. 2014;4(1): 22–33. doi: 10.2174/1871529x14666140401110841.

31. Gnudi L. Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association. Eur. Renal. 2012; 27(7):2642–9. doi: 10.1093/ndt/gfs121.

32. Sahakyan B, Klein K, Lee K, Tsai M. Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus. European Journal of Endocrinology. 2010;162:1101–1105. doi: 10.1530/EJE-10-0049.

33. Parikh A, Spencer F, Lessard D, et al. Venous thromboembolism in patients with reduced estimated GFR: a populationbased perspective. Am. J. Kidney Dis. 2011;58:746-755. doi: 10.1053/j.ajkd.2011.06.021.

34. Folsom A, Lutsey P, Astor B et al. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol. Dial. Transplant. 2010;25: 3296-3301. doi: 10.1093/ndt/gfq179.

35. Hughes S, Szeki I, Nash M, Thachil J. Anticoagulation in chronic kidney disease patients—the practical aspects. Clin Kidney J. 2014;7:442–449. doi: 10.1093/ckj/sfu080.

36. Ocak G, Verduijn M, Vossen C, et al. Chronic kidney disease stages 1–3 increase the risk of venous thrombosis. J Thromb Haemost. 2010; 8: 2428–2435. doi: 10.1111/j.1538-7836.2010.04048.x.

37. Kitamoto Y, Arizono K, Fukui H, Tomita K, Kitamura H, Taguma Y, et al.  Urinary Thrombin: A Novel Marker of Glomerular Inflammation for the Diagnosis of Crescentic Glomerulonephritis (Prospective Observational Study). PLoS ONE. 2015;10(3):e0118704. doi:10.1371/journal.pone.0118704.


Abstract views: 566
PDF Downloads: 16113
Published
2019-12-23
How to Cite
Dudar, I., & Mykhaloiko, I. (2019). The role of hemostatic disorders in the progression of chronic kidney disease. Ukrainian Journal of Nephrology and Dialysis, (4(64), 49-55. https://doi.org/10.31450/ukrjnd.4(64).2019.07
Issue
No 4(64) (2019): Ukrainian Journal of Nephrology and Dialysis
Section
Nephrology School